<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Battery Selloff on Korea Invest Insights</title><link>https://koreainvestinsights.com/tags/battery-selloff/</link><description>Recent content in Battery Selloff on Korea Invest Insights</description><generator>Hugo -- gohugo.io</generator><language>en</language><copyright>koreainvestinsights.com · @korea_invest_insights</copyright><lastBuildDate>Mon, 09 Nov 2026 23:38:28 +0900</lastBuildDate><atom:link href="https://koreainvestinsights.com/tags/battery-selloff/feed.xml" rel="self" type="application/rss+xml"/><item><title>Korea Quality Re-Rating Watch Nov 9: Hanmi Pharma &amp; Dongkuk Lead</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-09/</link><pubDate>Mon, 09 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-09/</guid><description>&lt;h2 id="macro-dashboard"&gt;Macro Dashboard
&lt;/h2&gt;&lt;p&gt;Today&amp;rsquo;s regime verdict is &lt;strong&gt;blocked&lt;/strong&gt; — the ETF creation proxy feed is stale, preventing a formal KR/US label. Available partial data as of Nov 9:&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th&gt;Level&lt;/th&gt;
 &lt;th&gt;Trend (5 obs)&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KR 3Y Bond&lt;/td&gt;
 &lt;td&gt;3.61%&lt;/td&gt;
 &lt;td&gt;–10 bps (Nov 6)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KR 10Y Bond&lt;/td&gt;
 &lt;td&gt;3.85%&lt;/td&gt;
 &lt;td&gt;–15 bps (Nov 6)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 2Y&lt;/td&gt;
 &lt;td&gt;4.46%&lt;/td&gt;
 &lt;td&gt;–15 bps (Nov 5)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td&gt;4.84%&lt;/td&gt;
 &lt;td&gt;–14 bps (Nov 5)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;WTI&lt;/td&gt;
 &lt;td&gt;$99.64&lt;/td&gt;
 &lt;td&gt;–$5.61 (Nov 3)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD Index&lt;/td&gt;
 &lt;td&gt;102.3&lt;/td&gt;
 &lt;td&gt;+0.42 (Nov 6)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td&gt;&lt;strong&gt;Stale&lt;/strong&gt;&lt;/td&gt;
 &lt;td&gt;Last observed Oct 30&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI / KOSDAQ&lt;/td&gt;
 &lt;td&gt;Not available&lt;/td&gt;
 &lt;td&gt;No index close in today&amp;rsquo;s feed&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Regime&lt;/strong&gt;: KR = UNKNOWN / US = UNKNOWN. Both rate curves stepped lower; HY OAS widened +22 bps. USD firm. No regime stance issued pending data refresh.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Market Snapshot, Nov 9. No full close briefing available; same-day DB used.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Korea&amp;rsquo;s market closed in soft territory. Of 2,599 listed names, 1,076 advanced and 1,274 declined — a slightly negative breadth count — but the average price change was +0.19%, signaling that gains concentrated in a handful of larger names masked broader selling.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Battery and EV complex under coordinated pressure.&lt;/strong&gt; The session&amp;rsquo;s loudest signal came from the battery chain. Samsung SDI (006400.KS) dropped –11.32% with both foreign and institutional investors selling simultaneously. LG Energy Solution (373220.KS) fell –5.78%, Eco Pro BM (247540.KQ) –8.66%, and Eco Pro (086520.KS) –8.46%. This is a cross-sector flush, not random noise, and aligns with global EV demand softness while WTI holds near $100.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Pharma and biotech diverged.&lt;/strong&gt; SK Bioscience (302440.KS) rose +5.21% on foreign buying. Samsung Biologics (207940.KS) edged down –0.40% but drew net institutional accumulation — a stabilizing pattern worth watching. The sector is bifurcated: CDMO and vaccine platforms attracting inflows, legacy names under pressure.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;IT services showed selective strength.&lt;/strong&gt; LG CNS (064400.KS) gained +4.32% with two-sided institutional and foreign buying — genuine shared conviction, not retail momentum. NAVER (035420.KS) slipped –1.63% but institutions were net buyers, pointing to quiet accumulation into weakness.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Airlines flagged by consensus upgrades.&lt;/strong&gt; Jeju Air (089590.KS) and Jin Air (272450.KS) both held their prices while sell-side analysts revised estimates higher — a setup where the market has not yet caught up to improving fundamentals.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Cosmetics sold off broadly.&lt;/strong&gt; Cosmax (192820.KS) –5.30% and Cosméka Korea (241710.KS) –15.09% saw coordinated foreign and institutional selling. The K-beauty complex faces a rough session on cross-border demand concerns.&lt;/p&gt;
&lt;p&gt;Overall character: &lt;strong&gt;selective rotation&lt;/strong&gt;. Capital moved away from batteries and cosmetics toward pharma CDMOs and IT services. Breadth was mildly negative, but several quality names are being quietly accumulated beneath the surface.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Meta Screener, Nov 9. The PEAD-only intersection found no 2+ screener overlaps today; candidates below are ranked by the Meta Screener&amp;rsquo;s composite weighted score, which applies historically calibrated weights: Consensus Up Revision (2.20×), RS80 Leadership (1.33×), financial factor screeners (0.58× each).&lt;/em&gt;&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th style="text-align: right"&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Meta Score&lt;/th&gt;
 &lt;th&gt;Screener Families&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Evidence Families&lt;/th&gt;
 &lt;th&gt;Key Signal&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;128940.KS&lt;/td&gt;
 &lt;td&gt;Hanmi Pharmaceutical&lt;/td&gt;
 &lt;td style="text-align: right"&gt;55.4&lt;/td&gt;
 &lt;td&gt;Consensus Up + Cycle + Smart Money Earnings + Smart Money Quality&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;Margin +2.2pp; foreign+institutional absorbed ₩80.7bn in 5d&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;121600.KQ&lt;/td&gt;
 &lt;td&gt;Nanoscale Materials&lt;/td&gt;
 &lt;td style="text-align: right"&gt;30.5&lt;/td&gt;
 &lt;td&gt;Consensus Up + Cycle&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +0.65; treasury share disposal filed Nov 6&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;086450.KS&lt;/td&gt;
 &lt;td&gt;Dongkuk Pharmaceutical&lt;/td&gt;
 &lt;td style="text-align: right"&gt;67.2&lt;/td&gt;
 &lt;td&gt;Quality Compounder + Cycle + PEAD + Quiet Accum&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;ROE 9.9%; OP YoY +20.1%; retail sold, smart money absorbed&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;002790.KS&lt;/td&gt;
 &lt;td&gt;Amorepacific Holdings&lt;/td&gt;
 &lt;td style="text-align: right"&gt;30.7&lt;/td&gt;
 &lt;td&gt;RS80 + Quiet Accum + Kiwoom Surface&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;RS80 Focus Candidate; pivot gap +4.6%; short interest 9.6%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;23.3&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +5.68 (highest in today&amp;rsquo;s table); IR held Nov 3&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;6&lt;/td&gt;
 &lt;td&gt;272450.KS&lt;/td&gt;
 &lt;td&gt;Jin Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;19.6&lt;/td&gt;
 &lt;td&gt;Consensus Up + Kiwoom&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +0.58; two IR catalysts filed Nov 6&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;7&lt;/td&gt;
 &lt;td&gt;383800.KS&lt;/td&gt;
 &lt;td&gt;LX Holdings&lt;/td&gt;
 &lt;td style="text-align: right"&gt;17.0&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;Consensus z +3.84; prelim earnings filed Nov 4&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;8&lt;/td&gt;
 &lt;td&gt;006730.KS&lt;/td&gt;
 &lt;td&gt;Seobu T&amp;amp;D&lt;/td&gt;
 &lt;td style="text-align: right"&gt;13.5&lt;/td&gt;
 &lt;td&gt;Consensus Up + Kiwoom&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Foreign rank #324; institutional rank #76; ownership 16.7%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;hr&gt;
&lt;h3 id="top-3-in-detail"&gt;Top 3 in Detail
&lt;/h3&gt;&lt;p&gt;&lt;strong&gt;1. Hanmi Pharmaceutical (128940.KS)&lt;/strong&gt;
Korea&amp;rsquo;s leading innovative pharma company, with biologics in diabetes/obesity, oncology, and rare diseases. It hits four screener families: Consensus Up, Cycle Rerating, Smart Money Earnings, and Smart Money Quality. Retail sellers offloaded approximately ₩64.5bn over the measurement period; foreign and quality-institutional buyers absorbed that supply — a classic divergence between weaker and stronger hands. Operating margin expanded +2.2pp. DART shows an active IR calendar and a confirmed licensing deal for LAGLA (Fabry disease treatment) filed Oct 30. &lt;strong&gt;Next check&lt;/strong&gt;: sell-side consensus revision size, LAGLA deal economics, and whether absorption holds this week.&lt;/p&gt;

 &lt;blockquote&gt;
 &lt;p&gt;&lt;strong&gt;Why ranked above Dongkuk despite lower raw score&lt;/strong&gt;: the Consensus Up family carries a 2.20× historical weight, well above the 0.58× applied to financial factor screeners. Hanmi&amp;rsquo;s estimate revision signal has stronger demonstrated forward-return lift in back-testing than a pure fundamental quality stack.&lt;/p&gt;

 &lt;/blockquote&gt;
&lt;p&gt;&lt;strong&gt;2. Nanoscale Materials (121600.KQ)&lt;/strong&gt;
Specialty materials supplier for semiconductor and display manufacturing. It appears in both Cycle Rerating and Consensus Up. The treasury share disposal filed Nov 6 is a capital allocation signal that often precedes positive management guidance. The consensus z-score is modest (+0.65) but directionally positive. &lt;strong&gt;Next check&lt;/strong&gt;: disposal structure (employee compensation vs. open-market sale), customer concentration in HBM or CXL-related substrate demand, and whether the cycle rerating is a leading or lagging read.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;3. Dongkuk Pharmaceutical (086450.KS)&lt;/strong&gt;
Domestic mid-cap pharma with stable consumer health and specialty drug divisions. The broadest fundamental case in today&amp;rsquo;s list: Quality Compounder, Cycle Rerating, PEAD, and Quiet Accumulation all trigger together. ROE 9.9%, OP YoY +20.1%, retail exit absorbed by institutional buyers. The PEAD screener places it in Tier C with a 52-week gap of 21.9% and price above MA50 — drift space remains open. Note: PEAD financial data is 242 days old (annual filing), so the most recent quarterly print needs independent verification. &lt;strong&gt;Next check&lt;/strong&gt;: Q3 2026 quarterly results, which product line is driving OP acceleration, and whether the quiet accumulation pattern precedes a disclosed catalyst.&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;&lt;em&gt;All names above are screener candidates flagged for further research — not buy or sell recommendations. Verify DART filings at source before acting on any signal.&lt;/em&gt;&lt;/p&gt;</description></item></channel></rss>